- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03938792
Estudio de eficacia y seguridad PF-06741086 en participantes adultos y adolescentes con hemofilia A grave o hemofilia B de moderadamente grave a grave
Un estudio abierto en adolescentes y adultos severos (actividad del factor de coagulación)
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Jeddah, Arabia Saudita, 21589
- King AbdulAziz University Hospital
-
Riyadh, Arabia Saudita
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Sofia, Bulgaria, 1756
- National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
-
Stara Zagora, Bulgaria, 6003
- UMHAT "Prof.Dr. Stoyan Kirkovich"
-
-
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8S 4K1
- McMaster University
-
Hamilton, Ontario, Canadá, L8S 4K1
- McMaster Children's Hospital
-
Hamilton, Ontario, Canadá, L8N 3Z5
- McMaster University Medical Centre - Hamilton Health Sciences
-
Toronto, Ontario, Canadá, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Daegu, Corea del Sur, 41944
- Kyungpook National University Hospital
-
Seoul, Corea del Sur, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Corea del Sur, 05278
- Kyung Hee University Hospital at Gangdong
-
-
-
-
-
Zagreb, Croacia, 10000
- Klinicki bolnicki centar Zagreb
-
-
-
-
-
A Coruña, España, 15006
- Hospital Universitario A Coruna
-
Barcelona, España, 08035
- Hospital Universitario Vall d´Hebron
-
Madrid, España, 28046
- Hospital Universitario La Paz
-
Salamanca, España, 37007
- Hospital Universitario De Salamanca
-
Zaragoza, España, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- USF Health Morsani Center for Advanced Healthcare
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa
-
-
New York
-
New Hyde Park, New York, Estados Unidos, 11040
- Northwell Health HTC
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Washington Institute for Coagulation
-
-
-
-
-
Paris, Francia, 75015
- Hôpital Necker Enfants malades
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
-
-
Gujarat
-
Surat, Gujarat, India, 395002
- Nirmal Hospital Pvt, Ltd
-
-
Maharashtra
-
Pune, Maharashtra, India, 411004
- Sahyadri Super Speciality Hospital
-
Pune, Maharashtra, India, 411004
- Sahyadri Clinical Research And Development Center
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, India, 632004
- Christian Medical College
-
-
-
-
-
Perugia, Italia, 06156
- Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
-
-
Milan
-
Milan, Milan, Italia, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
-
RM
-
Roma, RM, Italia, 00161
- Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
-
-
-
-
-
Hiroshima, Japón, 734-8551
- Hiroshima University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japón, 466-8560
- Nagoya University Hospital - Transfusion Medicine
-
-
Hokkaido
-
Sapporo, Hokkaido, Japón, 004-0041
- Sapporo Tokushukai Hospital
-
-
Saitama
-
Iruma-gun, Saitama, Japón, 350-0495
- Saitama Medical University Hospital
-
-
-
-
Nuevo León
-
Monterrey, Nuevo León, México, 64460
- Hospital Universitario "Dr Jose Eleuterio Gonzalez"
-
-
Yucatán
-
Mérida, Yucatán, México, 97130
- Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
-
-
-
-
-
Muscat, Omán, 123
- Sultan Qaboos University Hospital
-
-
-
-
-
Beijing, Porcelana, 100045
- Beijing Children's Hospital, Capital Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510515
- Nanfang Hospital, Southern Medical University
-
-
Guizhou
-
Guiyang, Guizhou, Porcelana, 550004
- The Affiliated Hospital of Guizhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana, 306113
- Jiangxi Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Porcelana, 300020
- Institute of Hematology, Chinese Academy of Medical Sciences
-
-
-
-
-
Samara, Rusia, 443079
- FGBOU VO "Samara State Medical University" of MoH of Russia
-
-
-
-
-
Belgrade, Serbia, 11000
- Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- Institute for Mother and Child healthcare "Dr Vukan Cupic"
-
Kragujevac, Serbia, 34000
- Clinical Center Kragujevac
-
Niš, Serbia, 18000
- Clinical Center Niš
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Sudáfrica, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Taichung, Taiwán, 40705
- Taichung Veterans General Hospital
-
-
Changhua County
-
Changhua, Changhua County, Taiwán, 500
- Changhua Christian Hospital
-
-
-
-
-
Adana, Turquía (Türkiye), 01130
- Acibadem Adana Hospital
-
Ankara, Turquía (Türkiye), 06230
- Hacettepe University Medical Faculty
-
Ankara, Turquía (Türkiye), 06500
- Gazi University Health Research and Practice Center Gazi Hospital
-
Antalya, Turquía (Türkiye), 07060
- Akdeniz University Medical Faculty
-
Gaziantep, Turquía (Türkiye), 27310
- Gaziantep University Sahinbey Research and Training Hospital
-
Istanbul, Turquía (Türkiye), 34093
- Istanbul University Oncology Institute
-
Izmir, Turquía (Türkiye), 35040
- Ege University Medical Faculty
-
Izmir, Turquía (Türkiye), 35210
- Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
-
Kayseri, Turquía (Türkiye), 38039
- Erciyes University Medical Faculty
-
Samsun, Turquía (Türkiye), 55280
- Ondokuz Mayıs University Medical Faculty
-
Trabzon, Turquía (Türkiye), 61080
- Karadeniz Technical University Medical Faculty
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Descripción
Criterios de inclusión
- Participantes con diagnóstico de hemofilia A grave o hemofilia B de moderadamente grave a grave con un peso mínimo de 35 kg en el momento de la selección.
- Participante o representante legalmente autorizado, o cuidador del participante capaz de dar consentimiento informado firmado (o asentimiento menor, cuando corresponda).
Los participantes que están inscritos en la cohorte de no inhibidores también deben cumplir con los siguientes criterios:
- Sin antecedentes detectables o documentados de inhibidores
- Participantes en profilaxis de rutina con FVIII/FIX que han demostrado al menos un 80 % de cumplimiento con el régimen de profilaxis programado durante los 6 meses anteriores a la inscripción y están dispuestos a continuar recibiendo tratamiento de profilaxis de rutina con reemplazo de FVIII/FIX durante la fase de observación.
- Participantes con régimen de tratamiento a demanda con ≥6 episodios de sangrado agudo (espontáneos o traumáticos) que requirieron infusión de factor de coagulación durante el período de 6 meses previo a la inscripción y que estén dispuestos a continuar recibiendo tratamiento a demanda durante la fase de observación.
Los participantes que están inscritos en la cohorte de inhibidores también deben cumplir con los siguientes criterios:
- Documentación de inhibidor de título alto actual (≥5 BU/mL) o inhibidor de título bajo actual (<5 BU/mL) refractario al reemplazo de FVIII o FIX y con recuperación de FVIII o FIX <60 % de lo esperado en los 6 meses anteriores a la inscripción en la fase de observación
- Participantes con hemofilia A con régimen de tratamiento a demanda con ≥6 episodios hemorrágicos o participantes con hemofilia B con ≥4 episodios hemorrágicos (espontáneos o traumáticos) que necesiten tratamiento con factor de derivación durante los 6 meses anteriores a la inscripción en la fase de observación y estén dispuestos a continuar recibiendo -Demandar tratamiento durante la Fase de Observación.
- Participantes que tienen inhibidores documentados mientras reciben terapia de reemplazo de factor pero que no cumplen con los criterios cuantitativos de inhibidores descritos en el punto anterior en el momento de la selección (p. ej., participante con un título alto de inhibidor previamente documentado (≥5 BU/ml) y cuya condición impide volver a desafiar con reemplazo de FVIII o FIX) puede ser considerado para la elegibilidad caso por caso con el acuerdo previo de Pfizer Medical Monitor
- Los participantes que cumplan con los criterios de sangrado mencionados anteriormente y que estén en profilaxis de rutina (definida como tratamiento mediante inyección IV de factor de derivación para prevenir el sangrado) y hayan demostrado al menos un 80 % de cumplimiento con el régimen de profilaxis programado durante los 6 meses anteriores a la inscripción, pueden ser considerado para la elegibilidad caso por caso con la discusión y el acuerdo del monitor médico de Pfizer.
Criterio de exclusión
- Tratamiento anterior o actual y/o antecedentes de enfermedades de las arterias coronarias, trombosis venosa o arterial o enfermedad isquémica
- Procedimiento quirúrgico planificado conocido durante el período de estudio planificado.
- Defecto hemostático conocido que no sea hemofilia A o B.
- Función renal o hepática anormal
- Enfermedad hepática o biliar inestable actual
- Parámetros hematológicos anormales
- Otra afección médica o psiquiátrica aguda o crónica o anormalidad de laboratorio que pueda aumentar el riesgo asociado con la participación en el estudio o la administración del producto en investigación o que pueda interferir con la interpretación de los resultados del estudio y, a juicio del investigador,
- Profilaxis de rutina actual con agente de derivación o terapia de reemplazo sin factor de coagulación, o cualquier tratamiento previo con un producto de terapia génica para el tratamiento de la hemofilia (los participantes tratados con profilaxis con agentes de derivación o que hayan recibido tratamiento previo con productos sin factor pueden ser considerado caso por caso).
Terapia concomitante regular con fármacos inmunomoduladores.
- Uso continuo o planificado de inducción de inmunotolerancia durante la Fase de observación o la Fase de tratamiento activo, o profilaxis con reemplazo de FVIII o FIX en cualquier momento después del inicio del tratamiento con la intervención del estudio durante la Fase de tratamiento activo
- Exposición previa a PF 06741086 durante la participación en los estudios B7841002 y B7841003.
- Participación en otros estudios que involucren medicamentos en investigación o vacunas en investigación dentro de los 30 días (o según lo determinen los requisitos locales) o 5 vidas medias antes del ingreso al estudio y/o durante la participación en el estudio.
- Recuento de células CD4 ≤200/uL si el virus de la inmunodeficiencia humana (VIH) es positivo
- ECG de detección que demuestre anormalidades clínicamente relevantes que puedan afectar la seguridad del participante o la interpretación de los resultados del estudio.
- Individuos con hipersensibilidad o una reacción alérgica a la proteína de hámster u otros componentes de la intervención del estudio.
- Miembros del personal del sitio del investigador directamente involucrados en la realización del estudio y sus familiares, miembros del personal del sitio supervisados por el investigador o participantes que sean empleados de Pfizer, incluidos sus familiares, directamente involucrados en la realización del estudio.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: PF-06741086
Los participantes serán asignados al tratamiento con PF-06741086 después de una fase de observación de 6 meses en su régimen de hemofilia actual.
|
Dosis de carga subcutánea (sc) de 300 miligramos (mg) seguida de 150 mg sq una vez a la semana (qw).
Se prescriben 300 mg sc qw para participantes que cumplen con los criterios de aumento de dosis.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
AEs included both serious AEs and all other AEs.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening.
A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: During prophylaxis treatment in ATP (12 months)
|
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response.
NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: During prophylaxis treatment in ATP (12 months)
|
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks.
Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up.
Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between.
Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: During prophylaxis treatment in ATP (12 months)
|
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling.
ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death.
In this outcome measure only categories with non-zero values reported.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
Height and weight were also measured and recorded.
Clinical significance in physical examinations was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure.
Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets.
Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium.
Clinical significance of laboratory parameters was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: During prophylaxis treatment in ATP (12 months)
|
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating.
Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
|
During prophylaxis treatment in ATP (12 months)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days.
Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Target joint: a major joint into which repeated bleeds occurred.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication).
Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed.
Total bleeds: Treated bleeds + untreated bleeds.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
Periodo de tiempo: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
PGIC-H at Month 6: Inhibitor Cohort
Periodo de tiempo: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
Periodo de tiempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Pfizer CT.gov Call Center, Pfizer
Publicaciones y enlaces útiles
Publicaciones Generales
- Matino D, Acharya SS, Taylor CT, Sun P, Agathon D, Raje S, Gould T, Palladino A, Mahlangu J, Lissitchkov T, Todorova M, Chan A, Carcao M, Sun J, Yang R, Wu R, Jin C, Zeng X, Boban A, Bilic E, Frenzel L, Fung Chan GC, Kong Li C, Apte S, Choraria N, Chistolini A, Marchesini E, Peyvandi F, Fujii T, Matsushita T, Kaneda M, Lyu CJ, Park YS, Kim S, Martinez LV, Adrian JM, Wali Y, Al Khabori M, Kurtov I, Alzahrani H, Zaher G, Micic D, Miljic P, Kostic G, Vucic M, Djurdjevic P, Hidalgo OB, Porras JG, Jimenez-Yuste V, Calvo Villas JM, Lopez Fernandez MF, Albayrak C, Okan V, Balkan C, Sahin F, Antmen A, Unal E, Visweshwar N, Sharathkumar A, Kruse-Jarres R. Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026 Feb 26;147(9):920-931. doi: 10.1182/blood.2025031065.
- Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, McDonald R, Acharya SS, Mahlangu J, Jimenez-Yuste V, Choraria N, Yang R, Li CK, Al-Khabori M, Wali Y, Morales Adrian J, Park YS, Zulfikar OB, Teeter J. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025 Oct 2;146(14):1654-1663. doi: 10.1182/blood.2024027468.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades Genéticas Congénitas
- Enfermedades hematológicas
- Trastornos de la coagulación de la sangre
- Trastornos hemorrágicos
- Enfermedades Genéticas, Ligadas al X
- Trastornos de la coagulación de la sangre, hereditarios
- Trastornos de proteínas de coagulación
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Hemofilia A
- Hemorragia
- Hemofilia B
- marstacimab
Otros números de identificación del estudio
- B7841005
- 2018-003660-31 (Número EudraCT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .